Gilead Sciences Inc. Share Price Today: Live Updates & Key Insights

Gilead Sciences Inc. share price today is $137.42, up -2.76%. The stock opened at $140.45 against the previous close of $141.11, with an intraday high of $141 and low of $136.79.

Gilead Sciences Inc. Share Price Chart

Gilead Sciences Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Gilead Sciences Inc. Share Price Performance

$137.42 -0.0276(-2.76%) GILD at 23 Mar 2026 01:19 PM Drug Manufacturers - General
Lowest Today 136.79
Highest Today 141
Today’s Open 140.45
Prev. Close 141.11
52 Week High 156.40
52 Week Low 90.95
Day’s Range: Low 136.79 High 141
52-Week Range: Low 90.95 High 156.40
1 day return -
1 Week return -5.47
1 month return -8.38
3 month return +10.54
6 month return +22.02
1 year return +28.67
3 year return +76.41
5 year return +109.41
10 year return -

Gilead Sciences Inc. Institutional Holdings

Vanguard Group Inc 9.75

BlackRock Inc 9.37

FMR Inc 5.28

State Street Corp 4.76

Capital World Investors 3.45

JPMorgan Chase & Co 3.41

Vanguard Total Stock Mkt Idx Inv 3.15

Vanguard 500 Index Investor 2.55

Geode Capital Management, LLC 2.39

T. Rowe Price Associates, Inc. 2.13

Invesco QQQ Trust 2.13

Dodge & Cox 2.12

Capital Research Global Investors 2.04

Morgan Stanley - Brokerage Accounts 1.91

NORGES BANK 1.72

Bank of America Corp 1.62

American Funds Income Fund of Amer A 1.58

Dodge & Cox Stock I 1.57

Wellington Management Company LLP 1.28

iShares Core S&P 500 ETF 1.27

Fidelity 500 Index 1.27

Amvescap Plc. 1.22

State Street® SPDR® S&P 500® ETF 1.18

Northern Trust Corp 1.15

Bank of New York Mellon Corp 1.15

UBS Asset Mgmt Americas Inc 1.05

American Funds Washington Mutual A 0.96

Capital Group Wash Mutual Invtrs Comp 0.96

Vanguard Value Index Inv 0.92

Legal & General Group PLC 0.83

Fidelity Contrafund 0.82

Amundi 0.77

State Street®HlthCrSelSectSPDR®ETF 0.74

American Funds American Balanced A 0.74

JPMorgan Large Cap Growth I 0.67

American Funds Capital Income Bldr A 0.65

Vanguard Equity-Income Inv 0.58

Vanguard Institutional Index I 0.57

JPM US Large Cap Growth-MA 0.57

State St S&P 500® Indx SL Cl III 0.53

Gilead Sciences Inc. Market Status

Strong Buy: 15

Buy: 4

Hold: 11

Sell: 0

Strong Sell: 0

Gilead Sciences Inc. Fundamentals

Market Cap 170335.32 M

PB Ratio 7.5031

PE Ratio 20.2375

Enterprise Value 185658.31 M

Total Assets 59023.00 M

Volume 15521887

Gilead Sciences Inc. Company Financials

Annual Revenue FY25:29443000000 29443.0M, FY24:28754000000 28754.0M, FY23:27391000000 27391.0M, FY22:27281000000 27281.0M, FY21:27305000000 27305.0M

Annual Profit FY25:25523000000 25523.0M, FY24:78200000 78.2M, FY23:21587000000 21587.0M, FY22:21624000000 21624.0M, FY21:20704000000 20704.0M

Annual Net worth FY25:8510000000 8510.0M, FY24:480000000 480.0M, FY23:5876000000 5876.0M, FY22:4592000000 4592.0M, FY21:6225000000 6225.0M

Quarterly Revenue Q4/2025:7925000000 7925.0M, Q3/2025:7769000000 7769.0M, Q2/2025:7081000000 7081.0M, Q1/2025:6667000000 6667.0M, Q4/2024:7569000000 7569.0M

Quarterly Profit Q4/2025:6882000000 6882.0M, Q3/2025:6200000000 6200.0M, Q2/2025:5580000000 5580.0M, Q1/2025:5127000000 5127.0M, Q4/2024:79000000 79.0M

Quarterly Net worth Q4/2025:2183000000 2183.0M, Q3/2025:3052000000 3052.0M, Q2/2025:1960000000 1960.0M, Q1/2025:1315000000 1315.0M, Q4/2024:1783000000 1783.0M

About Gilead Sciences Inc. & investment objective

Company Information Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Organisation Drug Manufacturers - General

Employees 17000

Industry Drug Manufacturers - General

CEO Mr. Daniel P. O'Day

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Gilead Sciences Inc. FAQs

What is the share price of Gilead Sciences Inc. today?

The current share price of Gilead Sciences Inc. is $137.42.

Can I buy Gilead Sciences Inc. shares in India?

Yes, Indian investors can buy Gilead Sciences Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Gilead Sciences Inc. shares in India?

You can easily invest in Gilead Sciences Inc. shares from India by:

Can I buy fractional shares of Gilead Sciences Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Gilead Sciences Inc.?

Gilead Sciences Inc. has a market cap of $170335.32 M.

In which sector does Gilead Sciences Inc. belong?

Gilead Sciences Inc. operates in the Drug Manufacturers - General sector.

What documents are required to invest in Gilead Sciences Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Gilead Sciences Inc.?

The PE ratio of Gilead Sciences Inc. is 20.24 and the PB ratio is 7.50.